These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6915075)

  • 21. A cluster of positively charged amino acids in the alpha-chain of C4b-binding protein (C4BP) is pivotal for the regulation of the complement system and the interaction with bacteria.
    Blom AM
    Scand J Clin Lab Invest Suppl; 2000; 233():37-49. PubMed ID: 11317941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
    Moore FD; Austen KF; Fearon DT
    J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase.
    Burge J; Nicholson-Weller A; Austen KF
    J Immunol; 1981 Jan; 126(1):232-5. PubMed ID: 6778916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
    Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
    Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
    Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
    J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The human alternative complement pathway: biology and immunopathology of activation and regulation.
    Kazatchkine MD; Nydegger UE
    Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132
    [No Abstract]   [Full Text] [Related]  

  • 27. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
    Ekdahl KN; Nilsson B
    J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations of complement components in disease.
    Luskin AT; Tobin MC
    Am J Med Technol; 1982 Sep; 48(9):749-56. PubMed ID: 6215862
    [No Abstract]   [Full Text] [Related]  

  • 29. Evidence for the involvement of arginine 462 and the flanking sequence of human C4 beta-chain in mediating C5 binding to the C4b subcomponent of the classical complement pathway C5 convertase.
    Ebanks RO; Isenman DE
    J Immunol; 1995 Mar; 154(6):2808-20. PubMed ID: 7876551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
    Rawal N; Pangburn MK
    Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
    Gyongyossy-Issa MI; McLeod E; Devine DV
    J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia.
    Cunnion KM; Benjamin DK; Hester CG; Frank MM
    J Lab Clin Med; 2004 Jun; 143(6):358-65. PubMed ID: 15192652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cytolytic C5b-9 complement complex: feedback inhibition of complement activation.
    Bhakdi S; Maillet F; Muhly M; Kazatchkine MD
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1912-6. PubMed ID: 3162317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
    Wagner E; Platt JL; Frank MM
    J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships.
    Kaplan AP; Ghebrehiwet B; Silverberg M; Sealey JE
    Crit Rev Immunol; 1981 Sep; 3(1):75-93. PubMed ID: 7047077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages.
    Daha MR; Van Es LA
    Immunology; 1981 Jul; 43(3):513-8. PubMed ID: 7251062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiological and pathological effects of activated complement.
    Dierich MP; Schulz T
    Haematologia (Budap); 1984; 17(1):3-16. PubMed ID: 6373514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defence mechanism.
    Ambrosio AR; De Messias-Reason IJ
    Parasite Immunol; 2005 Sep; 27(9):333-40. PubMed ID: 16149991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.